Fidia Farmaceutici S.p.a.

Monica Campisi

Anna Maria Zanellato

Giovanni Gennari

Davide Renier

Vincenza Corsa

Giancarlo Carpanese

Ottorino De Lucchi

Cristian Guarise

Riccardo Beninatto

Giuseppe Borsato

Pasquale Pierimarchi

Annalucia Serafino

The present invention relates to a multilayer composite material for the treatment of wounds and lesions and to a dressing comprising said multilayer material.

Multilayer composite material

Adhesive wound dressing that comprises an absorbent matrix (A) adhering to the central portion of a polyurethane backing (B) having an adhesive layer for the skin, said matrix (A) comprising: a. a breathable and porous polyethylene film at the end designed to come into contact with the wound; b. an absorbent layer made of non-woven fabric adjacent to film a), said absorbent layer consisting of: i. 60-65% viscose ii. 25-30% polyester iii. 5-15% polypropylene; c. a layer of polyethylene inserted between layer b) and a layer d. of hydrophobic polystyrene, the latter being in contact with the central portion of polyurethane backing (B); wherein matrix (A) is impregnated with a solution of one or more polysaccharides or the salts thereof.

Wound dressing for treatment of damaged skin

The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment of interstitial cystitis.

Pharmaceutical formulations comprising chondroitin sulfate and hyaluronic acid derivatives

Disclosed are photocrosslinked hyaluronic acid (HA) derivatives consisting of HA, a bifunctional polyethylene glycol (PEG) spacer which is triethylene glycol, and a photoreactive compound selected from a coumarin derivative and propiophenone.

Photocrosslinked hyaluronic acid derivatives, and the preparation process and use thereof

The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID&#xae;) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-Fluorouracyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behavior is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparations of derivative of ONCOFID&#xae; soluble in water. More specifically, the invention relates to the surprising biological and pharmacological effect demonstrated by formulations based on ONCOFID-S (HA-SN38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin.

Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias

The object of the present invention is novel release systems comprising specific hyaluronic acid amides combined with therapeutically and/or biologically active proteins with a mainly hydrophobic nature, for sustained, slow release over time which increases the efficacy of the medicament and the patient's compliance.

Growing community of inventors

Abano Terme, Italy

Monica Campisi